Results 71 to 80 of about 15,930 (153)

Cyclin dependent kinase 4/6 inhibitor palbociclib synergizes with BCL2 inhibitor venetoclax in experimental models of mantle cell lymphoma without RB1 deletion

Experimental Hematology & Oncology
Background Mantle cell lymphoma (MCL) is a chronically relapsing malignancy with deregulated cell cycle progression. We analyzed efficacy, mode of action, and predictive markers of susceptibility to palbociclib, an approved CDK 4/6 inhibitor, and its ...
Diana Malarikova, Radek Jorda, Kristyna Kupcova, Jana Senavova, Alexandra Dolnikova, Eva Pokorna, Dmitry Kazantsev, Kristina Nozickova, Dana Sovilj, Celine Bellanger, David Chiron, Ladislav Andera, Vladimir Krystof, Miroslav Strnad, Karel Helman, Magdalena Klanova, Marek Trneny, Ondrej Havranek, Pavel Klener   +18 more
doaj   +1 more source

TMEM45A enhances palbociclib resistance and cellular glycolysis by activating AKT/mTOR signaling pathway in HR+ breast cancer

Cell Death Discovery
Palbociclib, a CDK4/6 inhibitor, plays a crucial role in the treatment of HR+ breast cancer. However, resistance to palbociclib is a significant concern that merits further investigation.
Cui Chen, Zehong Chen, Jinze Zhao, Xinyun Wen, Hanming Yao, Zijin Weng, Huiping Xiong, Zongheng Zheng, Juekun Wu   +8 more
doaj   +1 more source

Lasofoxifene as a potential treatment for aromatase inhibitor-resistant ER-positive breast cancer

Breast Cancer Research
Background Breast cancers treated with aromatase inhibitors (AIs) can develop AI resistance, which is often driven by estrogen receptor-alpha (ERα/ESR1) activating mutations, as well as by ER-independent signaling pathways.
Muriel Lainé, Marianne E Greene, Justyna D Kurleto, Grazyna Bozek, Tiffany Leng, Rosemary J Huggins, Barry S Komm, Geoffrey L Greene   +7 more
doaj   +1 more source

Population Pharmacokinetic and Pharmacodynamic Study of Palbociclib in Children and Young Adults with Recurrent, Progressive, or Refractory Brain Tumors

Pharmaceutics
Background/Objectives: Palbociclib, an oral CDK 4/6 inhibitor, was evaluated in a Pediatric Brain Tumor Consortium (PBTC) phase 1 (NCT02255461; PBTC-042) study to treat children and young adults with recurrent, progressive, or refractory brain tumors ...
John C. Panetta, Nicholas S. Selvo, David Van Mater, Clinton F. Stewart   +3 more
doaj   +1 more source

Overall Survival With Palbociclib and Aromatase Inhibitor Versus Aromatase Inhibitor Alone in Older Patients With HR+/HER2− Metastatic Breast Cancer

Cancer Medicine
Introduction Cyclin‐dependent kinase 4/6 inhibitors (CDK4/6is) in combination with endocrine therapy are the current standard of care for first‐line (1L) treatment of hormone receptor–positive and human epidermal growth factor receptor 2–negative (HR ...
Adam M. Brufsky, Rickard Sandin, Stella Stergiopoulos, Connie Chen, Siddharth Karanth, Benjamin Li, Elizabeth Esterberg, Doris Makari, Sean D. Candrilli, Ravi K. Goyal, Hope S. Rugo   +10 more
doaj   +1 more source

Combined use of CDK4/6 and mTOR inhibitors induce synergistic growth arrest of diffuse intrinsic pontine glioma cells via mutual downregulation of mTORC1 activity

Cancer Management and Research, 2018
Daniel J Asby,1 Clare L Killick-Cole,1 Lisa J Boulter,1 William GB Singleton,1,2 Claire A Asby,3 Marcella J Wyatt,1 Neil U Barua,1,2 Alison S Bienemann,1 Steven S Gill1,2 1Functional Neurosurgery Research Group, Translational Health Sciences, Bristol ...
Asby DJ, Killick-Cole CL, Boulter LJ, Singleton WGB, Asby CA, Wyatt MJ, Barua NU, Bienemann AS, Gill SS   +8 more
doaj  

In vivo Pharmacokinetic Interactions Between Palbociclib and Rivaroxaban or Apixaban: Implications for Increased Drug Exposure and Dose Adjustments

Drug Design, Development and Therapy
Wenyu Du,1,2 Zihan Liu,1,2,* Ying Li,2,* Zhi Wang,2 Zhanjun Dong2 1Graduate School, Hebei Medical University, Shijiazhuang, 050017, People’s Republic of China; 2Hebei General Hospital, Hebei Key Laboratory of Clinical Pharmacy ...
Du W, Liu Z, Li Y, Wang Z, Dong Z
doaj  

Treatment Patterns and Clinical Outcomes Among Patients Receiving Palbociclib Combinations for Hormone Receptor-Positive (HR+)/Human Epidermal Growth Factor Receptor 2-Negative (HER2-) Advanced/Metastatic Breast Cancer in the Arabian Gulf Region: A Retrospective Study (TREASURE Study). [PDF]

Int J Breast Cancer
Dawoud E, Calaud F, Fadlelseid AA, Abdelhafeez N, Kullab S, Latif MF, Omara M, Tirmazy S, Hashiesh A, AlJabban A, Dawood S, Al-Foheidi M.   +11 more
europepmc   +1 more source

Genetic Variation in <i>NR1I2</i> and Palbociclib Safety and Prognosis in Advanced Breast Cancer: An Exploratory Multicenter Study. [PDF]

Int J Mol Sci
Arqueros C, Andrés M, Servitja S, Giner J, Tibau A, Borrell M, Martinez-Recio S, Barnadas A, Salazar J.   +8 more
europepmc   +1 more source

Distinct renal adverse event profiles among CDK4/6 inhibitors: a comparative pharmacovigilance analysis. [PDF]

Front Pharmacol
Guzel SS, Alan AM, Tay K, Demirci NS, Alan O.   +4 more
europepmc   +1 more source